Novartis AG
NVS
$164.70
$2.031.25%
NYSE
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 2.41B | 3.93B | 4.04B | 3.61B | 2.82B |
| Total Depreciation and Amortization | 1.18B | 1.26B | 1.16B | 1.15B | 1.17B |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 962.00M | 320.00M | 1.30B | 894.00M | 465.00M |
| Change in Net Operating Assets | -2.28B | 1.06B | 163.00M | -2.01B | -255.00M |
| Cash from Operations | 2.26B | 6.57B | 6.66B | 3.65B | 4.19B |
| Capital Expenditure | -609.00M | -354.00M | -331.00M | -254.00M | -558.00M |
| Sale of Property, Plant, and Equipment | 1.00M | 1.00M | 1.00M | 10.00M | 47.00M |
| Cash Acquisitions | -1.16B | -93.00M | -1.66B | -- | -426.00M |
| Divestitures | -9.00M | -64.00M | -11.00M | -4.00M | 164.00M |
| Other Investing Activities | -328.00M | -350.00M | -238.00M | 578.00M | -2.26B |
| Cash from Investing | -2.10B | -860.00M | -2.24B | 330.00M | -3.03B |
| Total Debt Issued | 5.13B | 135.00M | 850.00M | 556.00M | -24.00M |
| Total Debt Repaid | -1.84B | -646.00M | -669.00M | -1.08B | -82.00M |
| Issuance of Common Stock | 4.00M | 2.00M | 20.00M | 1.00M | 0.00 |
| Repurchase of Common Stock | -1.48B | -2.30B | -2.71B | -2.72B | -2.76B |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | 0.00 | -- | -2.49B | -5.33B | 0.00 |
| Other Financing Activities | -124.00M | 22.00M | -215.00M | 23.00M | -128.00M |
| Cash from Financing | 1.68B | -2.79B | -5.21B | -8.55B | -3.00B |
| Foreign Exchange rate Adjustments | 36.00M | -22.00M | 382.00M | 180.00M | -314.00M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1.88B | 2.90B | -410.00M | -4.39B | -2.15B |